Trades on 1 secondary market
Abata Therapeutics
Abata Therapeutics was a biotechnology company developing engineered regulatory T cell (Treg) therapies aimed at restoring immune tolerance in tissue-specific autoimmune and inflammatory diseases, with lead programs directed at progressive multiple sclerosis and type 1 diabetes. Founded in 2021 and
Abata Therapeutics is an API provider whose private shares are listed on 1 secondary market: Nasdaq Private Market.
Where It Trades
Listing data is compiled from the public marketplace pages of Forge Global, Hiive, EquityZen, Nasdaq Private Market, and Augment. A listing indicates that a venue has published a page for this company — it is not an offer, a quote, or investment advice, and APIs.io has no affiliation with any venue.